Secondary hormonal therapy for prostate cancer: What lies on the horizon?

Nima Sharifi*, William L. Dahut, William D. Figg

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

17 Scopus citations


Androgen deprivation therapy with medical or surgical castration is generally the first-line treatment against advanced prostate cancer. Almost invariably, metastatic prostate cancer overcomes testosterone depletion and grows, despite castrate levels of testosterone. Despite advances in cytotoxic chemotherapy, secondary hormonal therapies are often used after the development of castrate-resistant prostate cancer. Secondary hormonal therapies either lower the androgen levels further or directly antagonize the androgen receptor in prostate cancer cells. We discuss novel secondary hormonal agents that are under development, which work by either inhibiting androgen synthesis or directly targeting the androgen receptor.

Original languageEnglish
Pages (from-to)271-274
Number of pages4
JournalBJU International
Issue number3
StatePublished - Feb 2008
Externally publishedYes


Dive into the research topics of 'Secondary hormonal therapy for prostate cancer: What lies on the horizon?'. Together they form a unique fingerprint.

Cite this